A phase I trial of adjuvant chemotherapy using cetuximab (c) and docetaxel (t) for N2b-3 HNSCC patients with positive pathologic residual neck diseases after concurrent chemoradiation (CRT)
||Kenneth Hu, MD
| Time frame of study:
|Location of Study:
Mount Sinai Beth Israel
St.Luke's-Mount Sinai West
Continuum Cancer Research Program
Stage IVa (N2b-3) head and neck cancers usually treated with radiation and chemotherapy (cisplatin or carboplatin) followed by neck dissection (surgery). Previously, we have shown that subjects with remaining cancer shown on their neck dissection have an increased risk for having cancer develop and spread outside of the head and neck area, often to lungs or bones. In an attempt to prevent the spread of cancer, additional chemotherapy (cetuximab and taxotere) will be given to you on this study if you have remaining cancer after neck dissection.
- Age 18 and older
- subject with squamous cell cancers of the head and who have undergone concurrent chemoradiation (chemotherapy and radiation at the same time) and neck dissection
- No prior radiation therapy to the head and neck sites other than concurrent chemoradiation
Please call for more information.